Literature DB >> 3815408

Chemical synthesis and seroreactivity of O-(3,6-di-O-methyl-beta-D-glucopyranosyl)-(1----4)-O-(2,3-di-O-methyl- alpha-L-rhamnopyranosyl)-(1----9)-oxynonanoyl-bovine serum albumin--the leprosy-specific, natural disaccharide-octyl-neoglycoprotein.

D Chatterjee, S N Cho, P J Brennan, G O Aspinall.   

Abstract

The outer disaccharide segment, namely, O-(3,6-di-O-methyl-beta-D-glucopyranosyl)-(1----4)-2,3-di-O-methyl-alpha -L-rhamnopyranose, of the trisaccharide-containing, leprosy-specific, phenolic glycolipid I has been synthesized as the 8-(methoxycarbonyl)octyl glycoside in high yield and absolute stereospecificity by a series of modified Koenigs-Knorr and Helferich reactions. A particular feature of the synthetic pathway involves methylation of the 2-hydroxyl group of the rhamnose moiety under neutral conditions, after first preparing the 8-(methoxycarbonyl)octyl glycoside as the alpha anomer via the 1,2-orthoacetate, and thus precluding the possible formation of an anomeric mixture. The 8-(methoxycarbonyl)octyl O-(3,6-di-O-methyl-beta-D-glucopyranosyl)-(1----4)-2,3-di-O-methyl-alpha -L-rhamnopyranoside was converted into the crystalline hydrazide, and this was coupled to bovine serum albumin (BSA), via intermediate acyl-azide formation, to produce the corresponding neoglycoprotein, O-(3,6-di-O-methyl-beta-D-glucopyranosyl)- (1----4)-O-(2,3-di-O-methyl-alpha-L-rhamnopyranosyl)- (1----9)-oxynonanoyl-BSA, the so-called natural disaccharide-octyl-BSA. Extensive serological testing of this product against sera from leprosy patients and control populations, and comparison with the native glycolipid and previously synthesized neoglycoproteins, have shown that it is unparalleled in terms of sensitivity and specificity, and highly suited to replace the native glycolipid for the serodiagnosis of worldwide lepromatous leprosy.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3815408     DOI: 10.1016/s0008-6215(00)90098-3

Source DB:  PubMed          Journal:  Carbohydr Res        ISSN: 0008-6215            Impact factor:   2.104


  7 in total

1.  Detection of phenolic glycolipid I of Mycobacterium leprae in sera from leprosy patients before and after start of multidrug therapy.

Authors:  S N Cho; R V Cellona; L G Villahermosa; T T Fajardo; M V Balagon; R M Abalos; E V Tan; G P Walsh; J D Kim; P J Brennan
Journal:  Clin Diagn Lab Immunol       Date:  2001-01

2.  Novel gelatin particle agglutination test for serodiagnosis of leprosy in the field.

Authors:  S Izumi; T Fujiwara; M Ikeda; Y Nishimura; K Sugiyama; K Kawatsu
Journal:  J Clin Microbiol       Date:  1990-03       Impact factor: 5.948

Review 3.  Leprosy.

Authors:  R C Hastings; T P Gillis; J L Krahenbuhl; S G Franzblau
Journal:  Clin Microbiol Rev       Date:  1988-07       Impact factor: 26.132

4.  A modified synthesis and serological evaluation of neoglycoproteins containing the natural disaccharide of PGL-I from Mycobacterium leprae.

Authors:  Jian Zhang; Delphi Chatterjee; Patrick J Brennan; John S Spencer; Avraham Liav
Journal:  Bioorg Med Chem Lett       Date:  2010-04-21       Impact factor: 2.823

5.  Phenolic glycolipids of Mycobacterium bovis: new structures and synthesis of a corresponding seroreactive neoglycoprotein.

Authors:  D Chatterjee; C M Bozic; C Knisley; S N Cho; P J Brennan
Journal:  Infect Immun       Date:  1989-02       Impact factor: 3.441

6.  The mannose receptor mediates uptake of pathogenic and nonpathogenic mycobacteria and bypasses bactericidal responses in human macrophages.

Authors:  C Astarie-Dequeker; E N N'Diaye; V Le Cabec; M G Rittig; J Prandi; I Maridonneau-Parini
Journal:  Infect Immun       Date:  1999-02       Impact factor: 3.441

7.  Synthetic Phenolic Glycolipids for Application in Diagnostic Tests for Leprosy.

Authors:  J Hessel M van Dijk; Anouk van Hooij; L Melanie Groot; Jolijn Geboers; Rosita Moretti; Els Verhard-Seymonsbergen; Danielle de Jong; Gijs A van der Marel; Paul L A M Corstjens; Jeroen D C Codée; Annemieke Geluk
Journal:  Chembiochem       Date:  2021-02-10       Impact factor: 3.164

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.